New therapies will allow patients greater choice and
flexibility in the control of CNS disorders
BARCELONA, Spain, DÜSSELDORF,
Germany, and ATHENS, Greece, Dec. 12,
2024 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm),
a leading European specialty pharmaceutical company focused on the
treatment of central nervous system (CNS) disorders, and
Pharmathen, one of the largest pharmaceutical companies in
Greece and leaders in the
development and supply of long-acting injectable (LAI) therapies,
announce a strategic alliance to co-develop new long-acting
injectable therapies within the psychiatry field under Pharmathen's
long-acting therapeutic technologies (LATT) program.
Under this agreement, Neuraxpharm will have exclusive rights to
commercialise these therapies in Europe, and in countries outside of
Europe where the group has a
direct presence, while Pharmathen will have exclusive rights for
North America and all other
countries not covered by Neuraxpharm.
Pharmathen's LATT program uses its proprietary technologies to
replace traditionally available short acting dosage forms, such as
tablets or injectables, into longer acting injectable therapies to
address unmet needs of prescribers and patients. LATT support
better long-term control of symptoms, provide greater patient
compliance, and improved convenience in the treatment of
patients.
Pharmathen, with a proven track record in the development and
launch of LAI products globally, will be the technological,
manufacturing and supply partner. Neuraxpharm with its long-proven
commercialisation expertise for CNS products in Europe will register and market the products
across Europe and other direct
Neuraxpharm markets. Neuraxpharm is now established in more than 20
European countries, with affiliates in Latin America, the Middle East, and a global network of
distributors.
Commenting, Dr. Jörg-Thomas
Dierks, CEO, said: "Today's announcement reflects our
ongoing commitment to bringing innovative solutions to CNS patients
in Europe and beyond. These are
well established therapies, but we are bringing them to the market
in a new format, which will offer patients greater flexibility and
control in how they manage what are often challenging
conditions."
Dimitris Kadis, Group CEO
of Pharmathen, said: "At Pharmathen, our mission is to
improve patients' lives through innovation and quality. This
collaboration is an important step toward achieving that goal
by enhancing access, convenience, and choice for our patients
as we bring our long-acting therapeutic technology products to more
prescribers and CNS patients worldwide."
About the Neuraxpharm Group
Neuraxpharm is a leading European specialty pharmaceutical
company focused on the treatment of the central nervous system
(CNS), including both psychiatric and neurological disorders. It
has a unique understanding of the CNS market built over 35
years.
Neuraxpharm is constantly innovating, with new products and
solutions to address unmet patient needs and is expanding its
portfolio through its pipeline, partnerships, and acquisitions.
The company has c.1,000 employees and develops and
commercializes CNS products through a direct presence in more than
20 countries in Europe, two in
Latin America, one in the
Middle East, and globally via
partners in more than 50 countries. Neuraxpharm is backed by funds
advised by Permira.
Neuraxpharm manufactures many of its pharmaceutical products at
Neuraxpharm Pharmaceuticals (formerly Laboratorios Lesvi) in
Spain.
For more information, please visit
https://www.neuraxpharm.com
About Pharmathen
Founded in 1969, Pharmathen has evolved into one of the largest
vertically integrated companies developing innovative
pharmaceutical formulations. With top-level Research and
Development in cutting-edge technologies, Pharmathen today works on
one of the most complex and advanced portfolios, consisting of more
than 40 products, focusing on Injectable Sustained Release
Products, Controlled Release Formulations, and Ophthalmic products.
Its products are manufactured in the company's facilities in
Greece, which are approved by the
US Food and Drug Administration (FDA) and the European Union.
Pharmathen's highly diversified product portfolio, with more than
90 commercial products, is sold to 250 cooperating clients,
providing access to patients in more than 90 countries
worldwide.
For more information, please visit
https://www.pharmathen.com
View original
content:https://www.prnewswire.co.uk/news-releases/neuraxpharm-and-pharmathen-enter-into-strategic-co-development-agreement-to-develop-long-acting-injectable-therapies-302329350.html